Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 3/20 | 0.67 |
| ▸ | POLB | P06746 | 2/20 | 0.64 |
| ▸ | MTNR1A | P48039 | 7/20 | 0.62 |
| ▸ | MTNR1B | P49286 | 7/20 | 0.62 |
| ▸ | MEN1 | O00255 | 3/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.59 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.59 |
| ▸ | PRKG1 | Q13976 | 2/20 | 0.59 |
| ▸ | PRKACA | P17612 | 2/20 | 0.59 |
| ▸ | GSK3A | P49840 | 2/20 | 0.59 |
| ▸ | GSK3B | P49841 | 2/20 | 0.59 |
| ▸ | PRKX | P51817 | 2/20 | 0.59 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.59 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14380839 | 1.00 | ACACB (0.67) | ACACBPOLBMTNR1AMTNR1BMEN1 | |
| SCHEMBL13645878 | 0.87 | ACACB (0.58) | ACACBPOLBMTNR1AMTNR1BACACA | |
| SCHEMBL28360621 | 0.87 | POLB (0.64) | POLBMEN1KMT2ASMN1; SMN2ROCK1 | |
| SCHEMBL25274189 | 0.86 | POLB (0.63) | POLBMEN1KMT2ASMN1; SMN2ROCK1 | |
| SCHEMBL15831237 | 0.86 | POLB (0.63) | POLBMTNR1BMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL31173723 | 0.86 | POLB (0.63) | POLBMEN1KMT2ASMN1; SMN2ROCK1 | |
| SCHEMBL13853508 | 0.84 | SMN1; SMN2 (0.64) | POLBMEN1KMT2ASMN1; SMN2ROCK1 | |
| SCHEMBL13853510 | 0.84 | SMN1; SMN2 (0.64) | POLBMEN1KMT2ASMN1; SMN2ROCK1 | |
| SCHEMBL3724111 | 0.83 | ACACB (0.77) | ACACBMTNR1AMTNR1BACACA | |
| SCHEMBL17335677 | 0.83 | MEN1 (0.67) | POLBMTNR1AMTNR1BMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117730083-A | Pyrimidine compounds as MAP4K1 inhibitors | 格兰马克专业公司 | 2024-03-19 | — | — | CN | disclosed |
| CN-116897150-A | Novel bifunctional molecules for protein-targeted degradation | 安菲斯塔治疗有限公司 | 2023-10-17 | — | — | CN | disclosed |
| US-20230019032-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2023-01-19 | — | — | US | disclosed |
| US-11001575-B1 | Benzolactam compounds as protein kinase inhibitors | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-05-11 | — | — | US | disclosed |
| US-10457669-B2 | Benzolactam compounds as protein kinase inhibitors | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2019-10-29 | — | — | US | disclosed |
| US-20190047990-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2019-02-14 | — | — | US | disclosed |
| US-9616064-B2 | Rho kinase inhibitors and methods of use | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2017-04-11 | — | — | US | disclosed |
| US-20140179689-A1 | NOVEL RHO KINASE INHIBITORS AND METHODS OF USE | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2014-06-26 | — | — | US | disclosed |
| WO-2012135697-A2 | NOVEL RHO KINASE INHIBITORS AND METHODS OF USE | H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE INC. (US) | 2012-10-04 | — | — | WO | disclosed |
| EP-1630165-B1 | [1,2,4]TRIAZOLO[1,5-a]PYRIMIDIN-2-YLUREA DERIVATIVE AND USE THEREOF | NIPPON KAYAKU KK (JP) | 2010-03-31 | — | — | EP | disclosed |
| US-7598244-B2 | [1,2,4]triazolo[1,5,a]pyrimidin-2-ylurea derivative and use thereof | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2009-10-06 | — | — | US | disclosed |
| US-7598244-B2 | [1,2,4]triazolo[1,5,a]pyrimidin-2-ylurea derivative and use thereof | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2009-10-06 | — | — | US | disclosed |
| US-20070010515-A1 | [1,2,4] Triazolo [1,5, a] pyrimidin-2-ylurea derivative and use thereof | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2007-01-11 | — | — | US | disclosed |
| US-20070010515-A1 | [1,2,4] Triazolo [1,5, a] pyrimidin-2-ylurea derivative and use thereof | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2007-01-11 | — | — | US | disclosed |
| EP-1015444-B1 | PYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | YUHAN CORP LTD (KR) | 2003-05-28 | — | — | EP | disclosed |
| US-6352993-B1 | ANTIULCER AGENTS | YUHAN CORPORATION (KR) | 2002-03-05 | — | — | US | disclosed |
| EP-1015444-A1 | NOVEL PYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | YUHAN CORPORATION, LTD. (KR) | 2000-07-05 | — | — | EP | disclosed |
| WO-1998043968-A1 | NOVEL PYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | YUHAN CORPORATION (KR) | 1998-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010515-A1 | [1,2,4] Triazolo [1,5, a] pyrimidin-2-ylurea derivative and use thereof | HLA-C, TPMT, TAP1 | ACACB 4200/4885POLB 4498/4885MTNR1A 2091/4885 |
| US-20140179689-A1 | NOVEL RHO KINASE INHIBITORS AND METHODS OF USE | ROCK1, ROCK2, RHOA | ACACB 3086/4885POLB 3655/4885MTNR1A 1550/4885 |
| US-20230019032-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | MAPK1, ALK, MAP3K1 | ACACB 3916/4885POLB 2980/4885MTNR1A 823/4885 |
| US-20190047990-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | MAPK1, ALK, MAP3K1 | ACACB 3916/4885POLB 2980/4885MTNR1A 823/4885 |
| US-11001575-B1 | Benzolactam compounds as protein kinase inhibitors | MAPK1, ALK, MAP3K1 | ACACB 4000/4885POLB 2983/4885MTNR1A 773/4885 |
| US-10457669-B2 | Benzolactam compounds as protein kinase inhibitors | MAPK1, ALK, MAP3K1 | ACACB 3916/4885POLB 2980/4885MTNR1A 823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.